Cormorant fund sells 109,331 Bright Minds shares

Cormorant Global Healthcare Master Fund, LP, an entity associated with Cormorant Asset Management and Bihua Chen, reported an open-market sale of 109,331 common shares of Bright Minds Biosciences Inc. at $89.50 per share.

Rhea-AI Filing Summary

Cormorant Global Healthcare Master Fund, LP, an entity associated with Cormorant Asset Management and Bihua Chen, reported an open-market sale of 109,331 common shares of Bright Minds Biosciences Inc. at $89.50 per share.

After this transaction, the reporting structure shows 950,000 common shares indirectly held. The reporting persons, including Cormorant Asset Management and Bihua Chen, disclaim beneficial ownership of the reported shares except to the extent of their pecuniary interest.

Insider Trade Summary

Net Seller: 109,331 shares

Net Sell 1 txn

Insider Cormorant Asset Management, LP, Chen Bihua, Cormorant Global Healthcare Master Fund, LP

Role Insider | Insider | Insider

Sold 109,331 shs ($9.79M)

Type	Security	Shares	Price	Value
Sale	Common Shares	109,331	$89.50	$9.79M

Holdings After Transaction: Common Shares — 950,000 shares (Indirect, See Footnotes)

Footnotes (1)

1. F1. Cormorant Asset Management, LP ("Cormorant") serves as the investment manager of Cormorant Global Healthcare Master Fund, LP (the "Master Fund"). Cormorant Global Healthcare GP, LLC ("GP LLC") serves as the general partner of the Master Fund. Bihua Chen serves as the managing member of Cormorant, GP LLC and the Master Fund. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose.

Key Figures

Shares sold: 109,331 shares Sale price: $89.50 per share Shares held after sale: 950,000 shares

3 metrics

Shares sold 109,331 shares Open-market sale of common shares

Sale price $89.50 per share Price for sold common shares

Shares held after sale 950,000 shares Indirect ownership following transaction

Key Terms

open-market sale, indirect ownership, pecuniary interest, beneficial ownership, +1 more

5 terms

open-market sale financial

"transaction_action: "open-market sale""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

indirect ownership financial

"total_shares_following_transaction ... direct_or_indirect: "I""

pecuniary interest financial

"except to the extent of its or her pecuniary interest therein"

beneficial ownership financial

"disclaims beneficial ownership of the shares reported herein"

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

Section 16(a) regulatory

"for purposes of Section 16(a) of the Securities Exchange Act of 1934"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did BRIGHT MINDS BIOSCIENCES INC. (DRUG) report?

The filing reports an open-market sale of 109,331 common shares of Bright Minds Biosciences Inc. at $89.50 per share. The shares were sold by Cormorant Global Healthcare Master Fund, LP, an entity associated with Cormorant Asset Management and Bihua Chen.

Who is the selling holder in the BRIGHT MINDS BIOSCIENCES (DRUG) Form 4?

The sale is attributed to Cormorant Global Healthcare Master Fund, LP, with Cormorant Asset Management as investment manager and Bihua Chen as managing member. The reporting persons collectively disclaim beneficial ownership except for any pecuniary interest in the shares.

How many BRIGHT MINDS BIOSCIENCES (DRUG) shares are held after this Form 4 sale?

Following the reported transaction, the filing shows 950,000 common shares of Bright Minds Biosciences Inc. indirectly owned. This figure reflects the position after selling 109,331 shares and is reported under the indirect ownership structure described in the footnotes.

What price was received for the BRIGHT MINDS BIOSCIENCES (DRUG) shares sold?

The Form 4 states that 109,331 common shares of Bright Minds Biosciences Inc. were sold at a price of $89.50 per share. This was characterized as an open-market sale or private transaction under the Form 4 transaction code description.

How is beneficial ownership described for the BRIGHT MINDS BIOSCIENCES (DRUG) Form 4 reporters?

Cormorant Asset Management, Cormorant Global Healthcare Master Fund, and Bihua Chen each disclaim beneficial ownership of the reported shares, except to the extent of their pecuniary interest. The filing notes this disclaimer should not be construed as an admission of beneficial ownership.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/30/2026 - 04:07 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

X

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Cormorant Asset Management, LP

(Last) (First) (Middle)

200 CLARENDON STREET

52ND FLOOR

(Street)

BOSTON MASSACHUSETTS 02116

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
BRIGHT MINDS BIOSCIENCES INC. [ DRUG ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
	Officer (give title below)	X	Other (specify below)
			Former 10% Owner

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/28/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

	Form filed by One Reporting Person
X	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Shares	04/28/2026		S		109,331	D	$89.5	950,000	I	See Footnotes(1)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

1. Name and Address of Reporting Person^*

Cormorant Asset Management, LP

(Last) (First) (Middle)

200 CLARENDON STREET

52ND FLOOR

(Street)

BOSTON MASSACHUSETTS 02116

(City) (State) (Zip)

UNITED STATES

(Country)

Relationship of Reporting Person(s) to Issuer

	Director		10% Owner
	Officer (give title below)	X	Other (specify below)
			Former 10% Owner

1. Name and Address of Reporting Person^*

Chen Bihua

(Last) (First) (Middle)

C/O CORMORANT ASSET MANAGEMENT, LP

200 CLARENDON STREET, 52ND FLOOR

(Street)

BOSTON MASSACHUSETTS 02116

(City) (State) (Zip)

UNITED STATES

(Country)

Relationship of Reporting Person(s) to Issuer

	Director		10% Owner
	Officer (give title below)	X	Other (specify below)
			Former 10% Owner

1. Name and Address of Reporting Person^*

Cormorant Global Healthcare Master Fund, LP

(Last) (First) (Middle)

200 CLARENDON STREET

52ND FLOOR

(Street)

BOSTON MASSACHUSETTS 02116

(City) (State) (Zip)

UNITED STATES

(Country)

Relationship of Reporting Person(s) to Issuer

	Director		10% Owner
	Officer (give title below)	X	Other (specify below)
			Former 10% Owner

Explanation of Responses:

1. Cormorant Asset Management, LP ("Cormorant") serves as the investment manager of Cormorant Global Healthcare Master Fund, LP (the "Master Fund"). Cormorant Global Healthcare GP, LLC ("GP LLC") serves as the general partner of the Master Fund. Bihua Chen serves as the managing member of Cormorant, GP LLC and the Master Fund. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose.

	/s/ CORMORANT ASSET MANAGEMENT, LP By: Cormorant Asset Management GP, LLC, its General Partner	04/30/2026
	/s/ Bihua Chen	04/30/2026
	/s/ CORMORANT GLOBAL HEALTHCARE MASTER FUND, LP By: Cormorant Global Healthcare GP, LLC, its General Partner	04/30/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)